Kimball Electronics (KE) Q3 2025: Medical Sales Jump 22% as CMO Pivot Accelerates
Kimball Electronics delivered a sequential revenue increase, driven by a one-time medical consignment sale that lifted its medical vertical by 22%—underscoring a strategic pivot toward higher-margin contract manufacturing for medical devices (CMO, contract manufacturing organization). While automotive and industrial segments remain under pressure, the company is doubling down on medical expansion with a new Indianapolis facility and continued cost discipline, positioning for margin accretion and future growth despite ongoing tariff and demand uncertainties.
Summary
- Medical Expansion: New Indianapolis facility and strong medical sales mark a decisive shift in company focus.
- Operational Discipline: Inventory and cost controls improved cash flow and reduced debt, creating financial flexibility.
- Tariff and Demand Uncertainty: Macro headwinds and tariff unpredictability cloud near-term recovery for legacy EMS businesses.
Performance Analysis
Kimball Electronics produced sequential sales growth in Q3, with revenue totaling $375 million, up 5% from Q2. This was largely attributed to a $24 million non-recurring consignment sale in the medical vertical, which lifted medical sales by 22% and accounted for 6% of total company revenue for the quarter. Excluding the divested AT&M business, overall sales declined 10% year over year, reflecting continued softness in automotive and industrial segments.
Gross margin contracted to 7.2%, down 70 basis points YoY, primarily due to the low-margin nature of the consignment sale and lower absorption in EMS (electronics manufacturing services) facilities. However, margin improved sequentially as restructuring and cost initiatives took hold. Operating income margin landed at 4.2%, reflecting disciplined SG&A (selling, general & administrative) management, which fell to 3% of sales.
- Medical Vertical Surges: Medical now represents 31% of total sales, up from 28% last year, on the back of consignment and underlying growth.
- Automotive and Industrial Weakness: Automotive sales fell 14% YoY, while industrial dropped 15%, with both segments still digesting inventory and facing program roll-offs.
- Cash Flow and Inventory Management: Operating cash flow remained positive for the fifth consecutive quarter, inventory was reduced by $100 million YoY, and debt is now 45% below peak levels.
While non-recurring items flattered medical growth, underlying trends in automotive and industrial remain challenged, reinforcing the importance of the company’s medical pivot for long-term margin and revenue stability.
Executive Commentary
"We have ample liquidity to weather the short-term unpredictable environment and significant dry powder to opportunistically invest in the business longer term. As part of today's release, we are reiterating our guidance for fiscal 2025 with the expectation that we'll be at the top end of the range for sales and operating income. We also announced the addition of a new manufacturing facility in Indianapolis focused on the medical industry. This is another step of repositioning the company for a return to growth and expanding our presence as a medical CMO, which will occur over time."
Rick Phillips, Chief Executive Officer
"Cash flow generated by operating activities in the quarter was $30.9 million, our fifth consecutive quarter of positive cash flow. Cash conversion days were 99 days compared to 110 days in Q3 of fiscal 2024 and 107 days last quarter. The decrease in CCD this quarter compared to Q2 was driven by improvements in DSOs and PDSOH. We are pleased with the progress we've made related to cash conversion and look to continue to significantly improve our cash conversion days as we actively and aggressively manage its components."
Jana Kroon, Chief Financial Officer
Strategic Positioning
1. Medical CMO Focus and Facility Expansion
The addition of a 300,000-square-foot leased facility in Indianapolis marks a major strategic commitment to the medical contract manufacturing organization (CMO) model. This new site enables Kimball to pursue larger-scale, higher-margin medical device production, including finished assemblies and drug delivery devices. Leadership emphasized the flexibility and low upfront cost of the lease, designed to scale with demand while minimizing immediate financial drag.
2. Divestitures and Facility Rationalization
Kimball is actively streamlining its footprint, having divested the non-core AT&M business and moving to close its Tampa EMS facility by end of June. These moves improve capacity utilization and free capital for reinvestment into growth areas, especially medical CMO, while also driving incremental gross margin improvement as underperforming assets are exited.
3. Aggressive Cost and Inventory Management
Cost discipline is evident across SG&A, inventory, and debt reduction. SG&A was cut to 3% of sales, and inventory fell by $100 million YoY. Debt is now 40% lower than at the start of the fiscal year. These actions have improved cash conversion and liquidity, providing Kimball with “dry powder” to pursue organic and inorganic growth in medical manufacturing.
4. Navigating Tariff and Demand Volatility
Management remains highly cautious due to tariff uncertainty and unpredictable demand in legacy EMS verticals. The company is exploring options to mitigate tariff impacts, including shifting production and delivery locations, but acknowledges that the “rules of engagement” are still evolving. This uncertainty complicates forecasting and underscores the rationale for diversifying into medical CMO.
5. Platform Diversification and New Program Launches
Automotive and industrial segments are being repositioned, with new braking programs ramping in Europe and selective program launches in industrial. However, management does not expect smart meters to return as a meaningful growth driver, and is instead focused on new verticals such as climate control and charging infrastructure.
Key Considerations
Kimball’s Q3 results reflect both the benefits and limitations of a medical-driven pivot, with the company leveraging operational discipline to create headroom for future growth. However, the transition away from legacy EMS and industrial programs is ongoing, and the company’s ability to scale medical CMO will determine long-term margin and revenue trajectory.
Key Considerations:
- Medical Leverage: The Indianapolis expansion is designed to attract larger medical customers and enable higher-level assembly work, which could drive margin accretion over time.
- SG&A Flexibility: Management signaled that SG&A will not remain at 3% of sales as growth investments ramp, so investors should expect some expense normalization in FY26.
- Automotive Program Shifts: Major North American automotive braking programs are ending, but new European launches could offset declines if ramped successfully.
- Inventory and Cash Conversion: Continued reductions in inventory and improved cash conversion days signal strong operational discipline, but further gains may be incremental from here.
- Share Repurchases: With $19 million remaining on its buyback authorization, Kimball plans to continue repurchasing shares, reflecting confidence in balance sheet strength.
Risks
Tariff uncertainty and macro volatility remain the most significant near-term risks, with management explicitly stating that “one tweet” could upend margin and demand assumptions. The EMS business is exposed to ongoing program roll-offs and inventory digestion in automotive and industrial, while the CMO expansion requires successful customer onboarding and program scale-up to deliver targeted margin improvement. Expense normalization in FY26 could also pressure near-term earnings if growth lags.
Forward Outlook
For Q4 2025, Kimball guided to:
- Net sales at the high end of $1.4 to $1.44 billion annual range
- Adjusted operating income margin at the high end of 3.4% to 3.6%
For full-year 2025, management reiterated guidance and expects:
- CapEx at the low end of $40 to $50 million
Management highlighted:
- Restructuring benefits and Tampa closure on track to deliver incremental margin improvement
- Continued positive cash flow, with further inventory reductions and share repurchases expected
Takeaways
Kimball’s pivot to medical CMO is both a defensive and offensive play, aimed at offsetting EMS cyclicality and capturing higher-margin growth. The company’s operational discipline provides a solid foundation, but successful execution in new medical programs and managing through tariff headwinds will be critical.
- Medical CMO Execution: The ability to fill and scale the new Indianapolis facility will be the key determinant of margin and revenue trajectory in coming years.
- Legacy Program Risks: Automotive and industrial segments remain volatile, with program roll-offs and inventory digestion likely to weigh on near-term results.
- Expense and Investment Balance: Investors should monitor how SG&A and CapEx ramp as medical CMO growth accelerates, and whether incremental margin gains materialize as planned.
Conclusion
Kimball Electronics delivered sequential growth and improved cash flow in Q3, with a strategic pivot toward medical CMO now in full swing. While near-term headwinds persist in automotive and industrial, the company’s disciplined execution and focused capital allocation position it to benefit from medical market expansion if program execution meets expectations.
Industry Read-Through
Kimball’s results highlight a broader trend among EMS providers: pivoting into higher-margin, less cyclical verticals like medical device manufacturing as traditional automotive and industrial programs become more commoditized and exposed to macro volatility. The company’s facility rationalization, cost discipline, and emphasis on vertical integration in medical reflect moves that other EMS and contract manufacturers are likely to emulate. Tariff uncertainty, meanwhile, continues to cloud planning and may accelerate supply chain reconfiguration and U.S. manufacturing investments across the sector.